Clinical trials: for Brain Tumors
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma.
- Conditions
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease, Cystic Fibrosis, Fragile X Syndrome
- Trial name
- DANNIgene (NCT06147414)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Central Nervous System Carcinoma
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
This phase III trial compares memantine to placebo in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive…
- Trial name
- NCT04939597
- Testing
- Biospecimen Collection, Cognitive Assessment, Magnetic Resonance Imaging
- Where
- 138 sites in United States, Puerto Rico
- Volunteers
- 162 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Nonsmall Cell Lung Cancer
Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis
The need of radiosurgery is controversial for asymptomatic oligo brain metastasis for non small cell lung cancer (NSCLC). Therefore, the investigators do a randomized study comparing overall survival between two groups with or…
- Trial name
- NCT01301560
- Testing
- Radiosurgery, Observation
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Samsung Medical Center
Recurrent Glioblastoma
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
To learn if the Exablate Model 4000 Type 2 ("Exablate System") with the DEFINITY® ultrasound contrast agent can temporarily disrupt the blood brain barrier in patients with recurrent (has grown back) glioblastoma who are…
- Trial name
- NCT05879120
- Testing
- Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Dementia, Mild, Dementia of Alzheimer Type
Adaptation of the Uniform Data Set for Telematic Administration
The present project is an evolution of the previous RIN 2019 study aimed at validating and standardizing the Uniform Data Set (UDS) for dementia, a battery of tests exploring various cognitive domains (memory, language, praxis…
- Trial name
- NCT05785910
- Testing
- IUDS
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Osteogenesis Imperfecta, Osteoporosis
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia
- Trial name
- NCT07412782
- Testing
- REMS
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Meyer Children's Hospital IRCCS
Pituitary Adenoma
Molecular Pituitary Imaging Using 18F-FET PET
The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.
- Trial name
- FET-pit-PET (NCT06584123)
- Testing
- 18F-Fluoro-ethyl-tyrosine (FET) PET
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Cambridge
Medulloblastoma, Astrocytoma, Grade III
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies.
- Conditions
- Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02644291
- Testing
- Mebendazole
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cerebellar Function, Transcranial Magnetic Stimulation
Enhanced Recovery After Surgery Using TMS on Cerebellar Language Area for Brain Tumor Patients
At present, the incidence of language dysfunction in patients with brain language area tumor in the first month after operation was 20%-40%.
- Conditions
- Cerebellar Function, Transcranial Magnetic Stimulation, Language Disorders
- Trial name
- NCT03974659
- Testing
- Transcranial magnetic stimulation
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Huashan Hospital
DIPG, Brain Tumor, Pediatric, Recurrent
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require further treatment.
- Conditions
- DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity
- Trial name
- NCT04670016
- Testing
- This study does not include an intervention.
- Where
- 13 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Melanoma, Non-small Cell Lung Cancer
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
The purpose of this phase 2 trial is to study the activity of pembrolizumab in combination with bevacizumab in patients with untreated brain metastases from melanoma or NSCLC to determine activity and safety of the drug…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
- Trial name
- NCT02681549
- Testing
- Pembrolizumab plus Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Brain Tumor Adult
Feasibility Assessment of Adapted Physical Activity in Patients Treated for a Brain Tumor
The goal of this clinical trial is to assess the feasibility of an adapted physical activity (APA) program in adult patients (≥18 years) with primary brain tumors, regardless of tumor type, grade, treatment stage, or the presence…
- Trial name
- APATC (NCT07570485)
- Testing
- adapted physical activity
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Center Eugene Marquis
EGFR Positive Non-small Cell Lung Cancer, Brain Metastases
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Trial name
- NCT04643847
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- First People's Hospital of Hangzhou
Brain and Central Nervous System Tumors
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897663
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma (GBM)
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
This study aims to see if reducing blood sugar and increasing ketones (a metabolic product that comes from using fats for energy) can increase survival and enhance the the effects of standard radiation and chemotherapy treatments…
- Trial name
- NCT02046187
- Testing
- Ketogenic Diet, Radiation therapy, Temozolomide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Melanoma
PD-L1 PET Imaging in Melanoma Patients
This is a feasibility study for the use of [18F]PD-L1 as a PET tracer that will be conducted in a single center. The study consists of two phases.
- Trial name
- NCT03520634
- Testing
- PD-L1 PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Glioblastoma Multiforme, Anaplastic Astrocytoma
AZD8055 for Adults With Recurrent Gliomas
Background: AZD8055 is an experimental cancer treatment drug that works by inhibiting a protein called mTOR, which is known to promote tumor cell and blood vessel growth and to control tumor s energy and nutrient levels.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Malignant Glioma
- Trial name
- NCT01316809
- Testing
- AZD8055
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Hemangioma
Topical Timolol Gel for the Treatment of Infantile Hemangiomas
We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% .
- Trial name
- NCT02145884
- Testing
- timolol maleate 0.5% gel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rady Children's Hospital, San Diego
Brain Cancer
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
The study is designed to evaluate how the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis can predict the progression and outcomes of…
- Trial name
- BEAM (NCT01770626)
- Testing
- Nutrition
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham